Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
about
Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approachesTargeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.Effect of Hyperbaric Oxygen on the Growth of Intracranial Glioma in Rats.Glioma angiogenesis: Towards novel RNA therapeutics.Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenograftsRelative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastomaDexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Isthmin inhibits glioma growth through antiangiogenesis in vivoBevacizumab for the Treatment of Radiation-Induced Cerebral Necrosis: A Systematic Review of the Literature.BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.The Effectiveness of Bevacizumab in Radionecrosis After Radiosurgery of a Single Brain Metastasis.Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.Novel technologies for antiangiogenic drug delivery in the brain.The bright and the dark sides of DNA repair in stem cells.Drug delivery approaches for the treatment of glioblastoma multiforme.5'-AMP-activated protein kinase activity is elevated early during primary brain tumor development in the rat.Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival.Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
P2860
Q26865120-C608559F-3EA6-4CCF-B51B-BB982C0112C8Q27010580-E3B79515-4D5B-4333-80AD-6FC411345743Q30525687-0CD5B0D1-BCFA-44DC-8AA9-9460667BA7D3Q31028670-11B72D15-9EA3-49BD-A978-79B5ABFDACFBQ33414996-46DEE644-A19D-4025-8E91-8AB73B63D761Q33760569-10F3ECF5-8F0B-41EF-8CCC-3BB6A19FA9B9Q33786677-083025F8-8749-462B-9A7A-3D80FB173BC9Q33828114-85509829-AEBB-49A5-BBFE-E08E70F3EAF2Q34303312-0DC49548-EEDE-485F-B4BA-E55D632EAC7DQ35815295-5F79029F-EF9D-4FE8-8AFE-C735CE7803E9Q35863183-E8EFEF5A-028C-4512-991E-CA2B5580162FQ36103026-E5D06E84-4880-4EC0-95F6-07B5DCFAE11BQ36203492-B2C7ADE4-97F8-4B57-A05A-E7362DAEA395Q36300245-8B66FA09-3988-4EA8-8CEB-626A5581D043Q36347256-7F6D3CE7-90F8-439C-9AF0-5D40C4659B7EQ36438234-B2F636DD-09C6-4CAA-8420-DC139D7814B9Q36589758-9498ED52-30AC-4DFE-AF71-20528EB76E22Q37186246-283A1C4B-8E74-4BB1-854C-CECF7A6A0D6EQ37731956-BE6094AF-D068-4B43-8307-A0726DF4135EQ38517047-4ECA8CC4-DF11-40A3-BEA0-7AD85369C674Q41508406-8F129D2A-39A2-4DA1-A7F5-8D1EA2821863Q42642023-AB76D2FF-4670-4AFE-9011-7FFFFBE55337Q43517288-A5F6EA23-B703-4A1F-B1D2-570C21ECFE93Q48191891-9AE406BF-0FAD-4FAF-A83D-55FFCCD80A7E
P2860
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@ast
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@en
type
label
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@ast
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@en
prefLabel
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@ast
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@en
P356
P1476
Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
@en
P2093
Eric T Wong
Steven Brem
P304
P356
10.6004/JNCCN.2008.0039
P577
2008-05-01T00:00:00Z